Kristian Reich sold $1.2M of MLTX
Chief Scientific Officer at MoonLake Immunotherapeutics. 21,078 shares at an average of $57.33, traded Feb 20, 2024, filed Feb 22, 2024.
Score components
- +15RoleOfficer
- +25Trade size$1.2M at market
- 0Share of holdings soldSold 0.7% of holdings
- +8Cluster2 insiders selling within 14 days
- -2010b5-1 planPre-scheduled under a 10b5-1 plan
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
This signal so far: 1m -0.4%, 3m -23.5%, 6m -6.9%.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001213900-24-016240, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Feb 20, 2024 | SOpen-market sale Class A ordinary shares, par value $0.0001 per shareindirect: See footnote.10b5-1 | -10,000 | $57.45 | $575k | 2,987,483 | Feb 22, 2024 |
| Feb 20, 2024 | SOpen-market sale Class A ordinary shares, par value $0.0001 per share10b5-1 | -10,000 | $57.43 | $574k | 100,071 | Feb 22, 2024 |
| Feb 21, 2024 | SOpen-market sale Class A ordinary shares, par value $0.0001 per shareindirect: See footnote.10b5-1 | -509 | $55.31 | $28k | 2,986,974 | Feb 22, 2024 |
| Feb 21, 2024 | SOpen-market sale Class A ordinary shares, par value $0.0001 per share10b5-1 | -569 | $55.30 | $31k | 99,502 | Feb 22, 2024 |
Related signals
Other insiders at MoonLake Immunotherapeutics and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 0Weak | MoonLake Immunotherapeutics | Kristian Reich Chief Scientific Officer | $22k 1,100 shares | -0% | |
| 28Weak | MoonLake Immunotherapeutics | Kristian Reich Chief Scientific Officer | $1.0M 52,448 shares | -2% | |
| 26Weak | MoonLake Immunotherapeutics | Kristian Reich Chief Scientific Officer | $878k 43,700 shares | -2% | |
| 17Weak | MoonLake Immunotherapeutics | Kristian Reich Chief Scientific Officer | $322k 16,105 shares | -1% | |
| 38Weak | MoonLake Immunotherapeutics | da Silva Jorge Santos Chief Executive Officer | $2.0M 102,225 shares | -4% | |
| 44Moderate | MoonLake Immunotherapeutics | da Silva Jorge Santos Chief Executive Officer | $957k 47,775 shares | -2% | |
| 40Moderate | MoonLake Immunotherapeutics | Matthias Bodenstedt Chief Financial Officer | $862k 39,120 shares | -3% | |
| 32Weak | MoonLake Immunotherapeutics | Matthias Bodenstedt Chief Financial Officer | $352k 17,876 shares | -2% | |
| 28Weak | MoonLake Immunotherapeutics | Kristian Reich Chief Scientific Officer | $2.9M 150,000 shares | -5% | |
| 15Weak | MoonLake Immunotherapeutics | Matthias Bodenstedt Chief Financial Officer | $273k 13,653 shares | -1% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.